ROADMAP is a private-public partnership of leading institutions and companies with an interest in improving the situation of people with AD. Its goal is to develop efficient uses of real-world evidence (RWE) for the benefit of AD patients and their caregivers. ROADMAP aims to provide the foundation for a Europe-wide real-world evidence (RWE) platform in Alzheimer’s disease (AD) by piloting multimodal data integration tools and engaging with all key stakeholder groups for consensual definition of patient outcomes, tools and methods that are actionable and relevant.

As part of its extensive stakeholder engagement, ROADMAP partner Alzheimer Europe and colleagues at the University of Edinburgh previously held a consultation with the European Working Group of People with Dementia (EWGPWD) about outcome definitions in September 2017.

Read more>>